Search Results - ru+chih+huang

9 Results

Sort By:

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

Compositions Comprising NDGA Derivatives and Sorafenib and their Use in the Treatment of Cancer

INVENTION NOVELTYJHU investigators have combined the NDGA derivatives M4N and sorafenib to create a pharmaceutical composition that inhibits cancer cell growth. This novel drug combination has increased cytotoxic activity and inhibits growth of HCC human cancer cells in a dose-dependent manner.VALUE PROPOSITIONInvestigators have discovered a drug composition...

Published: 5/9/2024 | Inventor(s): Jong ho Chun, David Mold, Christopher Ruland, Yu-Chuan Liang, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Novel, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

C11620: Novel Treatment for Heart Attack

Novelty: The outlined invention features the novel therapeutic implications of a drug in preventing cardiac cell loss that occurs in myocardium infraction.Value Proposition: The technology describes the application of a drug to treat a major public health problem for which there is no current medical treatment option. The main features of the invention...

Published: 5/9/2024 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cardiovascular Diseases, Disease Indication, Myocardial Infarction, Myocardial Infarction (MI), Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular > Myocardial Infarction, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities

Rapid Induction of Human Cancer Cell Death by Synergistic Treatment of Tetra-O-Methyl Nordihydroguaiaretic Acid (M4N, Terameprocol) with 7-Hydroxystaurosporine (UCN-01)

Value Proposition: Tetra-O-methyl nordihydroguaiaretic acid (M4N, EM1421, Terameprocol), a novel transcription inhibitor, is an effective anticancer agent with excellent safety profile (Smolewski, P. Idrugs 11, 204-214, 2008). In the current study, we report an enhancement of anticancer activities of M4N in combination with 7-hydroxystaurosporine (UCN-01),...

Published: 5/9/2024 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Microenvironment-informed combinatorial therapy for hepatocellular carcinoma

Unmet NeedSorafenib, a kinase inhibitor, has been the gold-standard treatment for most individuals with hepatocellular carcinoma (HCC); however, studies suggest survival after treatment remains less than 15% (Raoul et al. 2019). Additionally, side effects, including hand-foot skin reactions and diarrhea, are prevalent in almost half of patients being...

Published: 5/9/2024 | Inventor(s): Ming Hsu, Jih-Ru Hwu, Szu Wu, David Mold, Ru Chih Huang

Keywords(s): Cancers, Disease Indication, Liver Cancer, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Hepatology, Clinical and Disease Specializations > Oncology > Liver Cancer, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology

A Bacterial Plasmid for High-throughput Screening of Gene Libraries that Uses Auto-induction to Initiate Protein Synthesis

Novelty: A self-inducing highly efficient protein expression system for high-throughput functional proteomics.Value Proposition: To date, the use of functional proteomics for clinical applications, such as the monitoring of molecular biotoxins and identification of disease biomarkers, is limited by the inconvenient manual regulation of plasmid transcription...

Published: 5/9/2024 | Inventor(s): Paul Giza, Ru Chih Huang

Keywords(s): Basic Research Biomarker, Cloning Reagents, Discovery/Research Tools, Plasmid, Proteomics/Immunoassays, Research Reagent

Category(s): Technology Classifications > Research Tools > Vectors & Plasmids, Technology Classifications > Research Tools

Rapid Induction of Cancer Cell Death by Synergistic Treatment of Tetra-O-methyl Nordihydroguaiaretic Acid (M4N) with either Rottlerin or Ly294002

Technical Details: M4N is an anti-cancer drug candidate, which is currently under the first phase of clinical trials. Although M4N can reduce tumor cell growth; it fails to induce quick tumor cell death. JHU scientists showed that the combination treatment of M4N with either two specific kinase inhibitors overcomes this problem. In vivo study demonstrated...

Published: 5/9/2024 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Targeted Therapy, Combination, Disease Indication, Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Development of a Combinational Paradigm Combating HIV, HIV/HSV or HIV/HPV Infections in Humans

Technical Details: WHO report has stated that there are 39.5 million people currently HIV positive worldwide. Of these, 4.3 million have been infected in the year 2006 alone. AIDS death reached 2.9 million this year which is the highest ever reported in any year. There are 40,000 new AIDS cases a year in U.S. along. The anti-HIV compounds that are currently...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Ibrahim Abd-Elazem

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Herpes Simplex Virus, Herpes Simplex Virus (HSV), HIV, HIV/AIDS, Infectious Diseases, Natural compounds, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Herpes Simplex Virus, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities

Antiviral Compositions and Methods of Use

Technical Details: This invention is related to isolation of two highly potent, non-toxic inhibitors against human immunodeficiency virus type 1 (HIV-1) integrase and viral replication. Two water soluble compounds, M522 and M532, have been discovered by isolating them from Salvia miltiorrhiza roots in purities of > 99.5 % as reported by NMR spectral...

Published: 5/9/2024 | Inventor(s): Ibrahim Abd-Elazem, Ru Chih Huang, Hongshan Chen

Keywords(s): Antagonists/Inhibitors, Disease Indication, HIV, HIV/AIDS, Infectious Diseases, Natural compounds, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities